Division of Gastroenterology and Nutrition, Children's Hospital Boston, Boston, Massachusetts 02115, USA.
Inflamm Bowel Dis. 2010 Oct;16(10):1669-77. doi: 10.1002/ibd.21214.
This study was designed to elucidate the contribution of parental height to the stature of children with inflammatory bowel disease (IBD), who often exhibit growth impairment. Accordingly, we compared patients' final adult heights and target heights based on measured parental heights and examined predictors of final adult height in pediatric IBD patients.
We prospectively analyzed the growth of 295 patients diagnosed between ages 1 and 18 (211 Crohn's disease [CD], 84 ulcerative colitis [UC]) and their family members (283 mothers, 231 fathers, 55 siblings).
Twenty-two percent had growth impairment (height for age Z-score <-1.64, equivalent to <5th percentile on growth curve) in more than 1 measurement since diagnosis; most growth-impaired patients had CD (88% CD versus 12% UC). Parents of the growth-impaired group had lower mean height Z-scores compared to parents of nongrowth-impaired patients (-0.67 versus 0.02 for mothers [P < 0.001]; -0.31 versus 0.22 for fathers [P = 0.002]). For 108 patients who reached adult heights and had available parental heights, the growth-impaired group continued to demonstrate lower adult height Z-scores (-1.38 versus 0.07; P < 0.001). Adult heights were within 1 SD of target heights even for the growth-impaired group. Only 11.3% remained persistently growth-impaired in adulthood. Multivariate regression analysis demonstrated lower parental height and minimum patient height Z-score as significant predictors of lower final adult height in IBD.
Parental height is a powerful determinant of linear growth even in the presence of chronic inflammation, and should be an integral part of the evaluation of growth in IBD children.
本研究旨在阐明父母身高对炎症性肠病(IBD)患儿身高的影响,这些患儿常出现生长障碍。因此,我们比较了患者的最终成人身高和靶身高,根据父母的实际身高进行测量,并研究了儿科 IBD 患者最终成人身高的预测因素。
我们前瞻性分析了 295 名 1 至 18 岁(211 名克罗恩病 [CD],84 名溃疡性结肠炎 [UC])确诊的患者及其家庭成员(283 名母亲、231 名父亲、55 名兄弟姐妹)的生长情况。
22%的患者在诊断后多次测量中出现生长障碍(身高年龄 Z 评分<-1.64,相当于生长曲线第 5 百分位数以下);大多数生长障碍患者患有 CD(88% CD 与 12% UC)。生长障碍组患者父母的平均身高 Z 评分低于无生长障碍患者父母的平均身高 Z 评分(母亲组为-0.67 与 0.02[P < 0.001];父亲组为-0.31 与 0.22[P = 0.002])。对于 108 名达到成人身高且有父母身高数据的患者,生长障碍组的成年身高 Z 评分仍较低(-1.38 与 0.07;P < 0.001)。即使是生长障碍组的患者,成年身高也在靶身高的 1 个标准差内。只有 11.3%的患者在成年后仍持续生长障碍。多变量回归分析表明,父母身高较低和患者最小身高 Z 评分是 IBD 患者最终成人身高较低的重要预测因素。
即使存在慢性炎症,父母身高也是线性生长的重要决定因素,应该是评估 IBD 患儿生长的一个重要组成部分。